Changes in Lung Function and Chylous Effusions in Patients with Lymphangioleiomyomatosis Treated with Sirolimus

Overview

Journal Ann Intern Med

Specialty General Medicine

Date 2011 Jun 22

PMID 21690594

Citations 90

Authors

Angelo M Taveira-DaSilva

Olanda Hathaway

Mario Stylianou

Joel Moss

Affiliations

Soon will be listed here.

Abstract

Background: Lymphangioleiomyomatosis (LAM) is a disorder that affects women and is characterized by cystic lung destruction, chylous effusions, lymphangioleiomyomas, and angiomyolipomas. It is caused by proliferation of abnormal smooth muscle-like cells. Sirolimus is a mammalian target of rapamycin inhibitor that has been reported to decrease the size of neoplastic growths in animal models of tuberous sclerosis complex and to reduce the size of angiomyolipomas and stabilize lung function in humans.

Objective: To assess whether sirolimus therapy is associated with improvement in lung function and a decrease in the size of chylous effusions and lymphangioleiomyomas in patients with LAM.

Design: Observational study.

Setting: The National Institutes of Health Clinical Center.

Patients: 19 patients with rapidly progressing LAM or chylous effusions.

Intervention: Treatment with sirolimus.

Measurements: Lung function and the size of chylous effusions and lymphangioleiomyomas before and during sirolimus therapy.

Results: Over a mean of 2.5 years before beginning sirolimus therapy, the mean (±SE) FEV1 decreased by 2.8%±0.8% predicted and diffusing capacity of the lung for carbon monoxide (Dlco) decreased by 4.8%±0.9% predicted per year. In contrast, over a mean of 2.6 years of sirolimus therapy, the mean (±SE) FEV1 increased by 1.8%±0.5% predicted and Dlco increased by 0.8%±0.5% predicted per year (P<0.001). After beginning sirolimus therapy, 12 patients with chylous effusions and 11 patients with lymphangioleiomyomas experienced almost complete resolution of these conditions. In 2 of the 12 patients, sirolimus therapy enabled discontinuation of pleural fluid drainage.

Limitations: This was an observational study. The resolution of effusions may have affected improvements in lung function.

Conclusion: Sirolimus therapy is associated with improvement or stabilization of lung function and reduction in the size of chylous effusions and lymphangioleiomyomas in patients with LAM.

Primary Funding Source: Intramural Research Program, National Heart, Lung, and Blood Institute, National Institutes of Health.

Citing Articles

Illness cognition, illness perception and related factors in patients with lymphangioleiomyomatosis.

Huang L, Yang L, Ouyang R, Ren S Orphanet J Rare Dis. 2025; 20(1):78.

PMID: 39972398 PMC: 11841310. DOI: 10.1186/s13023-025-03566-x.

Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis.

Baldi B, Feitosa P, Rubin A, Amaral A, Freitas C, Costa C J Bras Pneumol. 2025; 51(1):e20240378.

PMID: 39936727 PMC: 11796567. DOI: 10.36416/1806-3756/e20240378.

A chylothorax in a young woman: The difficulties of medical management.

Barton E, Johnson S, Collin N, Bhatt N, Maskell N Respirol Case Rep. 2024; 12(2):e01303.

PMID: 38371459 PMC: 10869891. DOI: 10.1002/rcr2.1303.

Lymphangioleiomyomatosis and mTOR inhibitors in real world-a narrative review.

Park S, Lee E J Thorac Dis. 2023; 15(11):6333-6344.

PMID: 38090328 PMC: 10713282. DOI: 10.21037/jtd-23-778.

Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis.

Worthy T, Jones A, Yang B, Ishiwata-Endo H, Gupta N, Moss J Chest. 2023; 165(2):303-306.

PMID: 37739031 PMC: 11026172. DOI: 10.1016/j.chest.2023.09.014.

References

McCormack F . Lymphangioleiomyomatosis: a clinical update. Chest. 2008; 133(2):507-16. DOI: 10.1378/chest.07-0898. View

Taveira-DaSilva A, Stylianou M, Hedin C, Hathaway O, Moss J . Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004; 126(6):1867-74. DOI: 10.1378/chest.126.6.1867. View

Goncharova E, Goncharov D, Eszterhas A, Hunter D, Glassberg M, Yeung R . Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002; 277(34):30958-67. DOI: 10.1074/jbc.M202678200. View

McCormack F, Inoue Y, Moss J, Singer L, Strange C, Nakata K . Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17):1595-606. PMC: 3118601. DOI: 10.1056/NEJMoa1100391. View

Sugimoto R, Nakao A, Yamane M, Toyooka S, Okazaki M, Aoe M . Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant. 2008; 27(8):921-4. DOI: 10.1016/j.healun.2008.05.012. View

COHEN M, Pollock-BarZiv S, Johnson S . Emerging clinical picture of lymphangioleiomyomatosis. Thorax. 2005; 60(10):875-9. PMC: 1747203. DOI: 10.1136/thx.2004.035154. View

Krymskaya V, Goncharova E . PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle. 2009; 8(3):403-13. PMC: 3718392. DOI: 10.4161/cc.8.3.7555. View

Franz D, Brody A, Meyer C, Leonard J, Chuck G, Dabora S . Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001; 164(4):661-8. DOI: 10.1164/ajrccm.164.4.2011025. View

Johnson S, Whale C, Hubbard R, Lewis S, Tattersfield A . Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004; 59(9):800-3. PMC: 1747117. DOI: 10.1136/thx.2004.023283. View

10.

Lamb R, Roy C, Diefenbach T, Vinters H, Johnson M, Jay D . The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol. 2000; 2(5):281-7. DOI: 10.1038/35010550. View

11.

Almoosa K, McCormack F, Sahn S . Pleural disease in lymphangioleiomyomatosis. Clin Chest Med. 2006; 27(2):355-68. DOI: 10.1016/j.ccm.2006.01.005. View

12.

Glasgow C, Taveira-DaSilva A, Pacheco-Rodriguez G, Steagall W, Tsukada K, Cai X . Involvement of lymphatics in lymphangioleiomyomatosis. Lymphat Res Biol. 2010; 7(4):221-8. PMC: 2883505. DOI: 10.1089/lrb.2009.0017. View

13.

Davies D, Johnson S, Tattersfield A, Kingswood J, Cox J, McCartney D . Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008; 358(2):200-3. DOI: 10.1056/NEJMc072500. View

14.

Osborne J, Fryer A, Webb D . Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991; 615:125-7. DOI: 10.1111/j.1749-6632.1991.tb37754.x. View

15.

Jaiswal V, Baird J, Fleming J, Miller D, Sharma S, Molberg K . Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med. 2003; 127(7):879-82. DOI: 10.5858/2003-127-879-LRLMM. View

16.

Lazor R, Valeyre D, Lacronique J, Wallaert B, Urban T, Cordier J . Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med. 2004; 98(6):536-41. DOI: 10.1016/j.rmed.2003.11.013. View

17.

Carsillo T, Astrinidis A, Henske E . Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000; 97(11):6085-90. PMC: 18562. DOI: 10.1073/pnas.97.11.6085. View

18.

Ryu J, Doerr C, Fisher S, Olson E, Sahn S . Chylothorax in lymphangioleiomyomatosis. Chest. 2003; 123(2):623-7. DOI: 10.1378/chest.123.2.623. View

19.

Gupta D, Ross K, Piacentino 3rd V, Stepnowski D, McClurken J, Furukawa S . Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax. Ann Thorac Surg. 2004; 78(1):e9-12. DOI: 10.1016/j.athoracsur.2003.12.069. View

20.

Tee A, Manning B, Roux P, Cantley L, Blenis J . Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003; 13(15):1259-68. DOI: 10.1016/s0960-9822(03)00506-2. View